Recent News

• 05.07.2026 - Alector Reports First Quarter 2026 Financial Results and Provides Business Update
• 04.29.2026 - Alector to Discontinue Phase 2 PROGRESS-AD Trial of Nivisnebart (AL101/GSK4527226) in Early Alzheimer’s Disease Following Interim Futility Analysis

Recent Filings

• 04.30.2026 - EFFECT Notice of Effectiveness
• 04.28.2026 - DEF 14A Other definitive proxy statements
• 04.28.2026 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
• 04.28.2026 - ARS Annual Report to Security Holders
• 04.27.2026 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 04.17.2026 - 4 Statement of changes in beneficial ownership of securities
• 04.16.2026 - 144 Report of proposed sale of securities
• 03.26.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 03.13.2026 - 4 Statement of changes in beneficial ownership of securities
• 03.13.2026 - 4 Statement of changes in beneficial ownership of securities